Cargando…
State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy
Cystic fibrosis (CF) is the most common life-limiting inherited disease in Caucasian populations, affecting approximately 80,000 people worldwide. CF is a complex multi-organ monogenic autosomal recessive disorder caused by a mutation in cystic fibrosis transmembrane conductance regulator (CFTR) gen...
Autores principales: | Meoli, Aniello, Fainardi, Valentina, Deolmi, Michela, Chiopris, Giulia, Marinelli, Francesca, Caminiti, Caterina, Esposito, Susanna, Pisi, Giovanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471029/ https://www.ncbi.nlm.nih.gov/pubmed/34577628 http://dx.doi.org/10.3390/ph14090928 |
Ejemplares similares
-
Impact of CFTR Modulators on the Impaired Function of Phagocytes in Cystic Fibrosis Lung Disease
por: Meoli, Aniello, et al.
Publicado: (2022) -
Non-Tuberculous Mycobacterial Diseases in Children
por: Meoli, Aniello, et al.
Publicado: (2020) -
A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy
por: Zaher, Anas, et al.
Publicado: (2021) -
The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability
por: Meng, Xin, et al.
Publicado: (2016) -
Early Origins of Chronic Obstructive Pulmonary Disease: Prenatal and Early Life Risk Factors
por: Deolmi, Michela, et al.
Publicado: (2023)